Phase 1 Relapsed Non Hodgkin Lymphoma Clinical Trials
9 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLarge B-cell Lymphoma+1 more
Lyell Immunopharma, Inc.270 enrolled34 locationsNCT05826535
Recruiting
Phase 1Phase 2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 1
SynKIR-310 for Relapsed/Refractory B-NHL
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma+23 more
Verismo Therapeutics36 enrolled5 locationsNCT06544265
Recruiting
Phase 1
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaNon-Hodgkin Lymphoma+7 more
Marcela V. Maus, M.D.,Ph.D.24 enrolled1 locationNCT06026319
Recruiting
Phase 1Phase 2
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Relapsed Pediatric ALLRelapsed Non Hodgkin LymphomaRelapsed Adult ALL
University of Alberta63 enrolled6 locationsNCT03938987
Recruiting
Phase 1Phase 2
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
High-grade B-cell LymphomaNon-Hodgkin LymphomaLymphoma+12 more
Estrella Biopharma, Inc.21 enrolled2 locationsNCT06343311
Recruiting
Phase 1Phase 2
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Multiple MyelomaNHLRefractory Non-Hodgkin Lymphoma+4 more
Indapta Therapeutics, INC.128 enrolled12 locationsNCT06119685
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Non-Hodgkin LymphomaLymphomaLymphoma, Non-Hodgkin+4 more
Caribou Biosciences, Inc.72 enrolled38 locationsNCT04637763
Recruiting
Phase 1
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Refractory Non-Hodgkin LymphomaRelapsed Non Hodgkin Lymphoma
SIRPant Immunotherapeutics, Inc.24 enrolled3 locationsNCT05967416